
DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION			
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION		
19701 Fairchild	3/4/2020-3/11/2020*		
Irvine, CA 92612-2445 (949)608-2900 Fax:(949)608-4417	FEI NUMBER 3009571102		
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	·		
Christine A. Givant, Co-Owner and Pharmacist in Charge			
FIRM NAME	STREET ADDRESS		
La Vita Compounding Pharmacy, LLC	3978 Sorrento Valley Blvd Ste 300		
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED		
San Diego, CA 92121-1436	Producer of Sterile and Non-Sterile Drugs		

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

## DURING AN INSPECTION OF YOUR FIRM WE OBSERVED: OBSERVATION 1

You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically, the firm purchases Methylcobalamin active ingredient from (b) (4) for use in the production of Methylcobalamin solution for injection. The firm has purchased and used  $\binom{(b)}{4}$  lots of this active ingredient that lacks a description of grade. These ungraded active ingredient batches were used in the production of  $\binom{(b)}{4}$  finished product batches:



## **OBSERVATION 2**

Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.

Specifically, on 3/9/20 we observed Sterile Technician <sup>(b) (6)</sup> gowning. The sleeves of the cleanroom suit (nonsterile) came in contact with the floor of the ISO 8 ante room. The technician proceeded to enter the ISO 5 zone and produce Methylcobalamin batch 183570@8 BUD 9/5/20. Uncovered and non-sanitized sleeves were observed within the ISO 5 space.

SEE REVERSE OF THIS PAGE	EMPLOYEE(S)SIGNATURE Zachary A Bogorad, Investi Nathaniel B Phillips Sylva		Zachary A Bogorad Investigator Signed By Zachary A Bogorad -S Date Signed 03-11-2020 15 09 57 X	DATE ISSUED 3/11/2020
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE I	SPECTIONAL OBSERVAT	IONS	PAGE 1 of 3 PAGES

	F HEALTH AND HUM ND DRUG ADMINISTRAT		
DISTRICT ADDRESS AND PHONE NUMBER		DATE(S) OF INSPECTION	
19701 Fairchild		3/4/2020-3/11/2020* FEI NUMBER	
Irvine, CA 92612-2445		3009571102	
(949)608-2900 Fax:(949)608-4417			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED			
Christine A. Givant, Co-Owner and Pha			
FIRM NAME	STREET ADDRESS		
La Vita Compounding Pharmacy, LLC		crento Valley Blvd Ste 300	
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHM		
San Diego, CA 92121-1436	Producer of Sterile and Non-Sterile Drugs		
The ISO 5 classified aseptic processing areas surface. Specifically, the following equipment conditions ISO5 zone: 1. Rust-like discoloration below the seat of the ch the seat of the chair on 3/4/20 while the room was 2. Rust-like discoloration of the garbage can w approximately 6 inches of the ISO 5 LAFH.	s were observed v nair at the ISO 5 L in a cleaned statu vas observed acros	within the ISO 7 buffer room containing the AFH. As well, white specks were observed or us. ss all surfaces. The can is positioned within	
<ul> <li>3. Extensive cracks are present on the (b) (4)</li> <li>the ISO 8 ante room respectively. More than</li> <li>(b) (4) is constructed of composite board w</li> <li>the ISO7 buffer room (b) (4)</li> </ul>	four cracks pass	through the entire depth of the <sup>(b) (4)</sup> The coating glued together. All materials entering	

contamination was found to be present in an area adjacent to the ISO 5 classified aseptic processing area during aseptic production.

Equipment within or in close proximity to the ISO 5 area could compromise the area in the ISO 5 area. Specifically, you keep a (b) (4) in the ISO 7 buffer room. During the cleanroom recertification activity on 1/25/19 third party cleanroom certification business <sup>(b) (4)</sup> identified an airborne viable environmental monitoring OOS (15 CFU) at location <sup>(b) (4)</sup>corresponding to the (b) (4) . The PIC identified a preventative action of not permitting the operation of the <sup>(b) (4)</sup> during cleanroom recertification activities and a

SEE REVERSE OF THIS PAGE	MPLOYEE(S)SIGNATURE Cachary A Bogorad, Investigator Nathaniel B Phillips Sylvain, Investigator		Zachary A. Bogorad investigator Signed by Zachary A. Bogorad -S Date Signed 03-11-2020 15:09:57	DATE ISSUED 3/11/2020
<u>.</u>				12
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	SPECTIONAL OBSERVAT	IONS	PAGE 2 of 3 PAGES

	DEPARTMENT OF HEAL	TH AND HUMAN SE	RVICES	
DISTRICT ADDRESS AND PHONE	FOOD AND DRUG	ADMINISTRATION	(S) OF INSPECTION	
19701 Fairchi			3/4/2020-3/11/2020*	
Irvine, CA 92			UMBER	
	Fax: (949)608-4417	30	09571102	
NAME AND TITLE OF INDIVIDUAL		the in Chang	0	
	Givant, Co-Owner and Pharmac	IST IN CHALY	e	
FIRM NAME	the stand Sto 300			00
	TYPE ESTABLISHMENT INSPECTED			
CITY, STATE, ZIP CODE, COUNT San Diego, CA		Producer of	Sterile and Non-Ste	erile Drugs
investigate and background to the		urce of air cor	itamination in the 150 h	
X 2020(wea			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
SEE REVERSE OF THIS PAGE	EMPLOYEE(S)SIGNATURE Zachary A Bogorad, Investig Nathaniel B Phillips Sylvai	ator n, Investiga	Signed By: Zachary A. Bogorad -S Date Signed: 03-11-2020 15:09:57	DATE ISSUED 3/11/2020
FORM FDA 483 (09/88)	PREVIOUS EDITION ORSOLETE IN	SPECTIONAL OBS	ERVATIONS	PAGE 3 of 3 PAGES

The observations of objectionable conditions and practices listed on the front of this form are reported:

- 1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or
- 2. To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration.

Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides:

"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."